Results 111 to 120 of about 11,998,196 (407)

Nutrigenomics: Using Sulforaphane Consumption as a Mechanism to Prevent Cardiovascular Disease through Epigenetic Regulation [PDF]

, 2018
Cardiovascular disease is the leading cause of death in the United States. Diet composition and reduced expression of the transcription factor Nrf2 are both possible factors contributing to cardiovascular disease.
Agrawal, Alisha
core   +1 more source

Association of high-sensitive C-reactive protein with advanced stage beta-cell dysfunction and insulin resistance in patients with type 2 diabetes mellitus [PDF]

, 2006
Background: Type 2 diabetes mellitus is associated with increased cardiovascular risk. One laboratory marker for cardiovascular risk assessment is high-sensitivity C-reactive protein (hsCRP).
Balkau, Forst, Haffner, Haffner, Hedblad, Howard, Huupponen, Langenfeld, Maseri, Matthews, Morrow, Nissen, Paice, Pfützner, Pfützner, Pfützner, Pfützner, Pfützner, Pfützner, Pfützner, Ridker, Ridker, Ridker, Ridker, Ridker, Ridker, Riveline, Ross, Saito, Sellmayer, Serrano Rios, Simpson, Willerson, Yudkin   +33 more
core   +1 more source

Kynurenic Acid Is a Predictive Prognostic Metabolic Marker in ST-Elevation Myocardial Infarction

Cardiovascular Therapeutics
Conclusions: The KYNA level may correspond to the underlying status of acute myocardial infarction and is a promising biomarker for predicting STEMI progression.
Xiaolin Zhang, Miaohan Qiu, Kun Na, Minghui Cheng, Haixu Song, Ning Zhao, Dan Liu, Chenghui Yan, Yaling Han   +8 more
doaj   +1 more source

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

New England Journal of Medicine, 2019
BACKGROUND The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium–glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is undefined. METHODS We randomly assigned patients with type 2 diabetes who
S. Wiviott, I. Raz, M. Bonaca, Ofri Mosenzon, Eri Toda Kato, A. Cahn, Michael G. Silverman, Thomas A. Zelniker, J. Kuder, S. Murphy, Deepak L. Bhatt, Lawrence A Leiter, Darren K Mcguire, J. Wilding, C. Ruff, I. Gause-Nilsson, M. Fredriksson, P. Johansson, A. Langkilde, M. Sabatine   +19 more
semanticscholar   +1 more source

Translating a Preclinically Tested 15 Hz rTMS Protocol to Humans With Chronic Spinal Cord Injury: A Safety and Feasibility Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives Repetitive transcranial magnetic stimulation (rTMS) is a non‐invasive brain stimulation strategy with a demonstrated potential to reinforce the residual pathways after a spinal cord injury (SCI). A preclinically tested high‐frequency (15 Hz) rTMS (15 Hz rTMS) protocol was shown to induce corticospinal tract axon regeneration growth ...
Nabila Brihmat, Mehmed B. Bayram, Morgan Paine, Janelle Carnahan, Jian Zhong, Xiaofei Guan, Guang H. Yue, Soha Saleh, Gail F. Forrest   +8 more
wiley   +1 more source

MicroRNAs in age-related diseases [PDF]

, 2013
Aging is a complex process that is linked to an increased incidence of major diseases such as cardiovascular and neurodegenerative disease, but also cancer and immune disorders.
Jazbutyte V, Olivieri F, Pierluigi Nicotera, Stefanie Dimmeler, Yang J   +4 more
core   +1 more source

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice.

European Heart Journal, 2021
F. Visseren, F. Mach, Y. Smulders, D. Carballo, K. Koskinas, Maria Bäck, A. Benetos, A. Biffi, J. Boavida, D. Capodanno, B. Cosyns, Carolyn B Crawford, C. Davos, I. Desormais, E. Angelantonio, O. Franco, S. Halvorsen, F. R. Hobbs, M. Hollander, E. Jankowska, M. Michal, Simona Sacco, N. Sattar, L. Tokgozoglu, S. Tonstad, K. Tsioufis, I. V. Dis, I. C. Gelder, C. Wanner, B. Williams, G. D. Backer, V. Regitz-Zagrosek, A. Aamodt, M. Abdelhamid, V. Aboyans, C. Albus, R. Asteggiano, Magnus Bäck, M. Borger, C. Brotons, J. Čelutkienė, R. Cífková, M. Čikeš, F. Cosentino, N. Dagres, T. D. Backer, D. Bacquer, V. Delgado, H. Ruijter, P. Dendale, H. Drexel, V. Falk, L. Fauchier, B. Ference, J. Ferrières, M. Ferrini, M. Fisher, D. Fliser, Z. Fras, D. Gaita, S. Giampaoli, S. Gielen, I. Graham, C. Jennings, T. Jørgensen, A. Kautzky-Willer, M. Kavousi, W. Koenig, A. Konradi, D. Kotecha, U. Landmesser, Madalena Lettino, B. Lewis, A. Linhart, M. Løchen, K. Makrilakis, G. Mancia, P. Marques-Vidal, J. McEvoy, Paul McGreavy, B. Merkely, L. Neubeck, J. Nielsen, J. Perk, Steffen E Petersen, A. Petronio, M. Piepoli, N. Pogosova, E. Prescott, K. Ray, Ž. Reiner, D. Richter, L. Rydén, E. Shlyakhto, M. Sitges, M. Sousa‐Uva, I. Sudano, M. Tiberi, R. Touyz, A. Ungar, W. Verschuren, O. Wiklund, D. Wood, J. Zamorano, Carolyn A Crawford, Oscar Durán   +105 more
semanticscholar   +1 more source

Medication Use in Multiple Sclerosis: A Population‐Based Comparison With the General Danish Population

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To investigate the overall use of prescription medications among individuals with multiple sclerosis compared to the general population, with a focus on treatments beyond disease‐modifying therapies. Methods We conducted a nationwide, registry‐based study in Denmark.
Josefine Windfeld‐Mathiasen, Henrik Horwitz, Ida M. Heerfordt, Elisabeth Framke, Melinda Magyari   +4 more
wiley   +1 more source

SYHA1813, A VEGFR and CSF1R Inhibitor, in Patients With Recurrent High‐Grade Gliomas: A Multicenter, Open‐Label Phase I Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Recurrent high‐grade gliomas have a poor prognosis and limited therapeutic options. This study aimed to evaluate the safety and efficacy of SYHA1813, a dual inhibitor of VEGFR and CSF1R, in patients with recurrent high‐grade gliomas.
Zhuang Kang, Shenglan Li, Liang Wang, Qianxue Chen, Weiguo Hu, Ting Lei, Ying Mao, Jing Zhang, Xiaojun Xiang, Qiming Wang, Zhengwen He, Tao Sun, Yulei Wang, Mengqian Huang, Rong Zhang, Feng Chen, Wenbin Li   +16 more
wiley   +1 more source

IgG anti-apolipoprotein A-1 antibodies in patients with systemic lupus erythematosus are associated with disease activity and corticosteroid therapy: an observational study. [PDF]

, 2015
IgG anti-apolipoprotein A-1 (IgG anti-apoA-1) antibodies are present in patients with systemic lupus erythematosus (SLE) and may link inflammatory disease activity and the increased risk of developing atherosclerosis and cardiovascular disease (CVD) in ...
Alber, KF, Bassett, P, Chambers, S, Croca, S, Davari, M, Giles, I, Ioannou, Y, Isenberg, D, Leach, O, Rahman, A   +9 more
core   +1 more source